Key clinical point: An autologous fecal transplant can restore intestinal microbiota after allogeneic hematopoietic stem cell transplant.
Major finding: All patients who received auto-FMT regained pre–allo-HSCT microbiota composition and diversity (P less than .0001).
Study details: An open-label study involving 25 allo-HSCT patients that compared auto-FMT with no treatment.
Disclosures: Study funding was provided by the Leonard Tow Foundation and the Memorial Sloan Kettering’s Center for Microbes, Inflammation, and Cancer. The authors reported disclosures related Merck, AbbVie, Nektar Therapeutics, Novartis, and others.
Taur Y et al. Sci Transl Med. 2018 Sep 26. doi: 10.1126/scitranslmed.aap9489.
This Week's Must Reads
Inadequate emergency care a challenge for rural pediatric patients, Walling EB et al. J Oncol Pract. 2019 Jan 31. doi: 10.1200/JOP.18.00115.
QC measures improve with CMS Oncology Care Model, Rocque G et al. J Oncol Pract. 2019. doi: 10. 1200/JOP.18.00390.
Women less likely to receive industry funds, Weng JK et al. JAMA Netw Open. 2019 Jan. 25. doi: 10.1001/jamanetworkopen.2018.7377.
A shift in Medicare drug coverage may boost costs for patients, Hwang TJ et al. JAMA Int Med. 2019. doi: 10.1001/jamainternmed.2018.6417.
President Trump requests $500 million for pediatric cancer, Trump D. State of the Union Address, Feb. 5, 2019.
Must Reads in Cellular Therapy
Tisagenlecleucel responses persist at 18 months in r/r B-cell ALL, Grupp SA et al. ASH 2018, Abstract 895
Ixazomib improves PFS after myeloma transplant, Dimopoulos MA et al. ASH 2018, Abstract 301
HSCT performs well in scleroderma-related lung disease, Goldin J et al. Arthritis Rheumatol. 2018;70(Suppl 10): Abstract 901
Immune system changes play a role in AML relapse, Christopher MJ et al. N Engl J Med. 2018 Oct 31. doi: 10.1056/NEJMoa1808777.
Auto-HSCT plus ablation in severe scleroderma, Sullivan KM et al. ACR Annual Meeting, Abstract 1820